Anti-TRAP220/MED1 antibody

• WB

Unknown

Western blot - Anti-TRAP220/MED1 antibody (AB64965)

The amount of positive control loading for the WB is 5-30 ug of total protein. The amount of the peptide for the WB is 5-10 ug.

All lanes:

Western blot - Anti-TRAP220/MED1 antibody (ab64965) at 1/500 dilution

Lane 1:

extracts from Jurkat cells, without immunising peptide

Lane 2:

extracts from Jurkat cells, with immunising peptide

Predicted band size: 168 kDa

Observed band size: 110 kDa,170 kDa

false

• IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAP220/MED1 antibody (AB64965)

Immunohistochemistry analysis of paraffin-embedded human breast carcinoma tissue using 1/50 ab64965, after antigen retrieval by boiling in a pressure cooker for 2-3 min. Polymer system was used for signal enhancing and DAB staining was performed for visualising the signal.

• WB

AbReview56755****

Western blot - Anti-TRAP220/MED1 antibody (AB64965)

Exposure time : 10 minutes.

All lanes:

Western blot - Anti-TRAP220/MED1 antibody (ab64965) at 1/1000 dilution

All lanes:

U-2 OS (human bone osteosarcoma epithelial cell line) whole cell lysate at 50 µg

Secondary

All lanes:

Alexa Fluor 680 anti-Rabbit

Predicted band size: 168 kDa

false

• WB

AbReview59308****

Western blot - Anti-TRAP220/MED1 antibody (AB64965)

Exposure time : 10 minutes

All lanes:

Western blot - Anti-TRAP220/MED1 antibody (ab64965) at 1/1000 dilution

All lanes:

MEF (Mouse embryonic fibroblast cell line) whole cell lysate at 20 µg

Secondary

All lanes:

Alexa Fluor 680 anti-Rabbit antibody at 1/5000 dilution

Predicted band size: 168 kDa

false

• WB

CiteAb

Western blot - Anti-TRAP220/MED1 antibody (AB64965)

TRAP220/MED1 western blot using anti-TRAP220/MED1 antibody ab64965. Publication image and figure legend from Jia, Y., Chang, H. C., et al., 2016, PLoS One, PubMed 27548259.

ab64965 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab64965 please see the product overview.

Tamoxifen-inducible cardiac-specific disruption of Med1 (TmcsMed1-/-) in adult mice causes dilated cardiomyopathy.(A) Relative Med1 mRNA expression in Med1fl/fl and TmcsMed1-/- mouse heart, liver and kidney. (B) Western blot analysis of Med1 in TmMed1fl/fl and TmcsMed1-/- hearts. Crude nuclear extracts from the heart tissues of appropriate mice were prepared as described (see Materials and Methods). They were then Western immunoblotted and probed with an anti-Med1 antibody (Abcam ab64965) and the protein bands were quantified using ImageJ software. The data were normalized to β-actin bands. Note that in the experiments shown in (A) to (H), mice were killed 14 days after first tamoxifen injection. (C) Representative photographs of adult hearts after tamoxifen-inducible heart-specific Cre mediated Med1 deletion. It is evident that TmcsMed-/- mouse heart is flaccid and flabby. Lower panel in (C) shows cross sections of TmcsMed1-/- and the littermate control hearts stained with H&E. (D and E) Representative profiles of M-mode echocardiographic analyses of TmcsMed1-/- and littermate mice. (F) and (G) represent ejection fraction and fractional shortening respectively. Data were derived from (D) and (E). (H), relative mRNA levels of BNP (Nppb) in Med1 fl/fl and TmcsMed1-/- mouse hearts. (I), survival curve. 13 mice for each group of Med1fl/fl and TmcsMed1-/- were used for the generation of survival curve. The mice survival time was between 13 and 28 days, and the day of initial injection of Tamoxifen was counted as day 1. Results are expressed as the mean ±SD. *p<0.05, **p<0.01.

false